Probiotics Dietary Supplements Market Size, Share, Trends, Innovations, Outlook 2022-2030

The global Probiotics Dietary Supplements market size is expected to be worth around US$ 15.28 billion by 2030, according to a new report by Vision Research Reports.

The global Probiotics Dietary Supplements market size was valued at US$ 7,122.5 million in 2020 and is anticipated to grow at a CAGR of 8.0% during forecast period 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38959

Report Coverage

Report Scope	Details
Market Size	US$ 15.28 Billion by 2030
Growth Rate	CAGR of 8.0% From 2021 to 2030
Base Year	2021
Forecast Period	2021 to 2030
Segments Covered	Form, End-user
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned	Probi; Vitakem Nutraceutical, Inc.; Chr. Hansen Holding A/S; ProbioFerm; Probium; ADM; Dr. Joseph Mercola; Deerland Probiotics and Enzymes, Inc.; DSM; BioGaia

Growth Factors

The growing demand for solutions over concerns related to digestive health is expected to augment the market growth. Diarrhea, nausea, and vomiting are a few of the symptoms observed in COVID-19 patients. Studies on using probiotics against coronavirus infection have been carried out since the disease outbreak in 2020.

The potential of probiotics in improving the symptoms of COVID-19 is expected to boost market growth. The rising application scope of probiotics in feminine health is further expected to fuel the product demand. Poor urogenital health due to microbial imbalance can lead to the occurrence of conditions, such as infertility, bacterial vaginosis, and preterm birth in women.

By Form Analysis

The capsules segment dominated the market with a share of more than 33.8% in 2020. Capsules, such as Capsugel DRcaps, have a modified release mechanism that is intended for targeted release of probiotics in the gut that increases its absorption efficiency compared to traditional capsules.

Powders are easy to consume for people having difficulties swallowing capsules or tablets. Thus, manufacturers are developing products in powder form that are readily mixed with water, juice, or milk.

The chewables & gummies segment is estimated to register the fastest CAGR over the forecast period as products in the forms are sweet and easy to consume. Products development efforts for targeted delivery of tablets are expected to support the growth of the tablet segment.

By End-user Analysis

The adults segment dominated the market with a revenue share of 53.7% in 2020. Rising cases of gastrointestinal problems in adults have pushed the development of probiotic supplements.

Probiotic supplements for infants are commonly offered in powder or liquid forms, wherein the products do not have their own taste. These products therefore can be easily mixed with infant formulas, pumped breast milk, and other liquids that are fed to the baby.

Players are focusing on offering probiotic supplements providing solutions to health concerns related to children. For instance, the Culturelle brand offers Culturelle Kids Ultimate Balance for Antibiotics, which are chewable tablets for children in the age group of 3 to 12 years.

Reported cases of deaths due to intestinal inflammation and other irritable bowel disorders, such as Crohn’s disease and ulcerative colitis, have been rising among the older population in the recent past.

By Regional Analysis

North America emerged as one of the most prominent regional markets accounting for a revenue share of 40% in 2020. North America has a vast population facing rising cases of obesity and digestive distress on account of their dietary habits.

Europe is expected to grow at a significant CAGR of 7.3% over the forecast period owing to the rising adoption of supplement products. For instance, as per Synadiet Survey 2020, about 36% of the surveyed population in France consumed food supplements and natural health products to boost immunity after the emergence of COVID-19.

Asia Pacific is likely to register the fastest CAGR from 2020 to 2030. The players are focusing on enhancing the efficiency of their products using advanced technologies to gain a strong market foothold.

By Regional Analysis

North America emerged as one of the most prominent regional markets accounting for a revenue share of 39% in 2020. North America has a vast population facing rising cases of obesity and digestive distress on account of their dietary habits.

Europe is expected to grow at a significant CAGR of 7.3% over the forecast period owing to the rising adoption of supplement products.

Asia Pacific is likely to register the fastest CAGR from 2020 to 2030. The players are focusing on enhancing the efficiency of their products using advanced technologies to gain a strong market foothold. The product demand in Central & South America is primarily driven by the rising governmental initiatives for health and nutrition in countries, such as Brazil.

Key Players

• Probi
• Vitakem Nutraceutical, Inc.
• Chr. Hansen Holding A/S
• ProbioFerm
• Probium
• ADM
• Dr. Joseph Mercola
• Deerland Probiotics and Enzymes, Inc.
• DSM
• BioGaia

Market Segmentation

• By Form
  • Chewables & Gummies
  • Capsules
  • Powders
  • Tablets & Softgels
  • Others
• By End-user
  • Infants
  • Children
  • Adults
  • Geriatric
• Regional
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
  • Central & South America (CSA)
    • Brazil
  • Middle East & Africa (MEA)
    • South Africa

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38959

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Probiotics Dietary Supplements Market, By Form

7.1.  Probiotics Dietary Supplements Market, by Form, 2021-2030

7.1.1.    Chewables & Gummies

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Capsules

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Powders

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Tablets & Softgels

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Probiotics Dietary Supplements Market, By End-user

8.1.  Probiotics Dietary Supplements Market, by End-user, 2021-2030

8.1.1.    Infants

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Children

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Adults

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Geriatric

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Probiotics Dietary Supplements Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Form (2017-2030)

9.1.2.    Market Revenue and Forecast, by End-user (2017-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Form (2017-2030)

9.1.3.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Form (2017-2030)

9.1.4.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Form (2017-2030)

9.2.2.    Market Revenue and Forecast, by End-user (2017-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Form (2017-2030)

9.2.3.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Form (2017-2030)

9.2.4.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Form (2017-2030)

9.2.5.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Form (2017-2030)

9.2.6.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Form (2017-2030)

9.3.2.    Market Revenue and Forecast, by End-user (2017-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Form (2017-2030)

9.3.3.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Form (2017-2030)

9.3.4.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Form (2017-2030)

9.3.5.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Form (2017-2030)

9.3.6.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Form (2017-2030)

9.4.2.    Market Revenue and Forecast, by End-user (2017-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Form (2017-2030)

9.4.3.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Form (2017-2030)

9.4.4.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Form (2017-2030)

9.4.5.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Form (2017-2030)

9.4.6.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Form (2017-2030)

9.5.2.    Market Revenue and Forecast, by End-user (2017-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Form (2017-2030)

9.5.3.2.        Market Revenue and Forecast, by End-user (2017-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Form (2017-2030)

9.5.4.2.        Market Revenue and Forecast, by End-user (2017-2030)

Chapter 10.  Company Profiles

10.1.              Probi

10.1.1.  Company Overview

10.1.2.  Form Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Vitakem Nutraceutical, Inc.

10.2.1.  Company Overview

10.2.2.  Form Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Chr. Hansen Holding A/S

10.3.1.  Company Overview

10.3.2.  Form Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              ProbioFerm

10.4.1.  Company Overview

10.4.2.  Form Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Probium

10.5.1.  Company Overview

10.5.2.  Form Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              ADM

10.6.1.  Company Overview

10.6.2.  Form Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Dr. Joseph Mercola

10.7.1.  Company Overview

10.7.2.  Form Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Deerland Probiotics and Enzymes, Inc.

10.8.1.  Company Overview

10.8.2.  Form Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              DSM

10.9.1.  Company Overview

10.9.2.  Form Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           BioGaia

10.10.1.               Company Overview

10.10.2.               Form Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

12.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38959

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com